OnCo

Penile cancer: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersRisk group
Early / localised·1
Second line1·
Other settings2·

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
Risk groupClinically node-negative, intermediate or high-risk primaryDynamic sentinel node biopsy (or modified inguinal lymphadenectomy where unavailable); observation only for low-risk primaries.68

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersMetastatic or recurrentCisplatin-based chemotherapy (TIP); checkpoint inhibitors in trials or where approved for tumour-agnostic indications; palliative radiotherapy.98

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersPrimary tumourOrgan-sparing treatment where feasible (glansectomy, glans resurfacing, wide local excision, laser or brachytherapy); partial or total penectomy reserved for extensive tumours.40
All comersNode-positiveRadical inguinal lymphadenectomy; pelvic lymphadenectomy and adjuvant chemotherapy or chemoradiation for extensive disease; neoadjuvant TIP for bulky or fixed nodes (InPACT is testing the sequence).81

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.